Administration of Low-dose IL-2 in Established T1D
Conditions: Diabetes Mellitus, Type 1; Diabetes; Diabetes, Autoimmune Interventions: Drug: Proleukin® (Aldesleukin; IL-2); Drug: Placebo - Concentrate Sponsors: Jay S. Skyler; National Institute of Allergy and Infectious Diseases (NIAID); Diabetes Research Institute Foundation; University of Florida; University of California, San Francisco Not yet recruiting - verified August 2017
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Allergy | Allergy & Immunology | Autoimmune Disease | Diabetes | Endocrinology | Infectious Diseases | Research